Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New study shows hope for treating inhalant abuse

01.10.2004


GVG may reduce addictive effects of ’huffing’



A new study by scientists at the U.S. Department of Energy’s Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA or GVG) may block the addictive effects of toluene, a substance found in many household products commonly used as inhalants. These results broaden the promise of GVG as a potential treatment for a variety of addictions. The study will be published in the December 1, 2004 issue of Synapse, available online September 30.

Inhalant abuse or "huffing" continues to grow as a serious health problem: According to the National Institute on Drug Abuse, the number of new inhalant users increased from 627,000 in 1994 to 1.2 million in 2000. The chronic use of inhalants has been associated with heart, liver, kidney, and brain damage -- and can even result in sudden death.


The Brookhaven Lab study demonstrates that animals previously trained to expect toluene in a given location spent far less time "seeking" toluene in that location after being treated with GVG than animals treated with a placebo. This elimination of conditioned place preference -- a model of craving in which animals develop a preference for a place where they have previously had access to a drug, even when the drug is absent -- is similar to the aversion seen in Brookhaven’s earlier studies of GVG with nicotine and heroin.

"The findings of this study extend the potential value of GVG to treat addiction," says Stephen Dewey, the Brookhaven Lab neuroanatomist who led the study. "More importantly, our results show promise in treating inhalant abuse as it continues to grow as a problem among adolescents." There are currently no pharmaceutical treatments for inhalant abuse.

The study was conducted by putting rats through a series of conditioning tests. The tests were intended to condition the animals to learn which chambers of a three-chambered apparatus contained toluene vapors. On the final day of the study, scientists randomly administered either saline or GVG to the rats one hour before the testing. They then gave the rats free access to the chambers with no toluene present while monitoring the animals’ behavior.

Researchers found that animals treated with GVG spent 80 seconds on the side of the chamber where they had previously received toluene as compared to the saline-treated animals, which spent 349 seconds in the "toluene" chamber. "GVG significantly blocked toluene-seeking behavior in these rats," Dewey said.

Earlier research at Brookhaven Lab demonstrated the addictive nature of inhalants. A team led by Dewey found that toluene elevates dopamine in the same regions of the brain as other addictive drugs, such as cocaine. The neurotransmitter dopamine is associated with the activation of pleasure and reward circuits in the brain.

Inhalant abuse is among the most common forms of drug abuse, particularly among pre- and early adolescents, who inhale or "huff" chemical vapors found in many common household products that are not generally thought of as drugs. Seventy-one percent of inhalant users are 12 to 25 year olds, according to the 2002 National Survey on Drug Use and Health performed by the U.S. Substance Abuse & Mental Health Services Administration.

Stephen Dewey and Jonathan Brodie, a psychiatrist at the New York University School of Medicine, have collaborated at Brookhaven Lab on a large body of preclinical research on GVG as a potential treatment for addiction, and on two small-scale trials of GVG in Mexico [one published http://www.bnl.gov/bnlweb/pubaf/pr/2003/bnlpr092203a.asp, one yet-to-be published]. Results from the preclinical and early clinical trials show that GVG holds promise as a treatment for addiction to a variety of abused drugs (see: http://www.bnl.gov/pet/GVG/default.asp).

In October 2002, Catalyst Pharmaceutical Partners of Coral Gables, Florida (http://www.catalystpharma.com), received an exclusive worldwide license from Brookhaven Science Associates, operator of Brookhaven National Laboratory, for the use of the drug GVG for its application in treating drug addiction.

Dennis Tartaglia | EurekAlert!
Further information:
http://www.mbooth.com
http://www.bnl.gov
http://www.nida.nih.gov

More articles from Studies and Analyses:

nachricht Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>